## CONTENTS

**JANUARY 2014**

### NEWS IN BRIEF

- Important news stories affecting the community .......................... 6
- Q&A: Mitchell Zeller on the FDA and Tobacco ............... 10
- The Science of Tobacco Addiction and Cessation .......... 12

### NEWS IN DEPTH

- Selected highlights of recent articles of exceptional significance from the cancer literature ............... 14

### ONLINE

- For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

### IN THIS ISSUE

- Highlighted research articles ........................................ 1

### REVIEW

- Antiangiogenic Therapies: Going beyond Their Limits ........ 31
  L. Moserle, G. Jiménez-Valerio, and O. Casanovas

### RESEARCH BRIEFS

- mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 ............. 42
- Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity ......... 53
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition .......... 61

### VIEWS

- In The Spotlight
  - Climbing RAS, the Everest of Oncogenes ....................... 19
    M. Russo, F. Di Nicolantonio, and A. Bardelli
    See article, p. 42
  - miR-30c-2-3p and miR-30a-3p: New Pieces of the Jigsaw Puzzle in HIF2α Regulation ...... 22
    H. Moch and M. Lukamowicz-Rajska
    See article, p. 53
  - Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis ....25
    R.A. Brekken
    See article, p. 110

- In Focus
  - Towards a Unified Model of RAF Inhibitor Resistance ........ 27
    D.B. Solit and N. Rosen
    See articles, p. 61, p. 69, p. 80, p. 94

---

In Focus

Towards a Unified Model of RAF Inhibitor Resistance ........ 27
D.B. Solit and N. Rosen
See articles, p. 61, p. 69, p. 80, p. 94
Using data from a high-throughput drug screen, Faber and colleagues found that AZD8055, an inhibitor of mTOR complexes 1 and 2 (TORC1/2), cooperated with the BCL-2/BCL-XL inhibitor ABT-263 to induce cell-cycle arrest and apoptosis specifically in \textit{KRAS}- and \textit{BRAF}-mutant colorectal cancer cell lines. This genotype selectivity was mediated by suppression of the antiapoptotic protein MCL-1 and disruption of BIM–MCL-1 complexes in response to TORC1/2 inhibition, which sensitized \textit{KRAS}-mutant cells to ABT-263 and triggered apoptosis. Furthermore, dual treatment with ABT-263 and AZD8055 preferentially induced tumor regression in \textit{KRAS}-mutant colorectal cancer xenograft and genetically engineered mouse models. These results support further clinical development of this therapeutic combination for patients with \textit{KRAS}- and \textit{BRAF}-mutant colorectal cancer. For details, please see the article by Faber and colleagues on page 42.

\textbf{AC icon indicates Author Choice}

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org. Online-only News stories include the following:

- NCI Issues Omics Checklist for Tests
- Obinutuzumab Breaks through to FDA Approval
- ICR Expands CanSAR Drug Discovery Platform
- ASCO Forges Ahead with CancerLinQ
- HPV Vaccine Works against Nine Viral Types
- Ibrutinib Approved for Mantle Cell Lymphoma

\textbf{ON THE COVER} Using data from a high-throughput drug screen, Faber and colleagues found that AZD8055, an inhibitor of mTOR complexes 1 and 2 (TORC1/2), cooperated with the BCL-2/BCL-XL inhibitor ABT-263 to induce cell-cycle arrest and apoptosis specifically in \textit{KRAS}- and \textit{BRAF}-mutant colorectal cancer cell lines. This genotype selectivity was mediated by suppression of the antiapoptotic protein MCL-1 and disruption of BIM–MCL-1 complexes in response to TORC1/2 inhibition, which sensitized \textit{KRAS}-mutant cells to ABT-263 and triggered apoptosis. Furthermore, dual treatment with ABT-263 and AZD8055 preferentially induced tumor regression in \textit{KRAS}-mutant colorectal cancer xenograft and genetically engineered mouse models. These results support further clinical development of this therapeutic combination for patients with \textit{KRAS}- and \textit{BRAF}-mutant colorectal cancer. For details, please see the article by Faber and colleagues on page 42.